CRISPR 및 Cas 유전자 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 컴포넌트별, 용도별, 프로세스별, 최종 사용자별, 기능별(-2035년)

The global CRISPR And Cas Genes Market is projected to grow from $5.1 billion in 2025 to $29.3 billion by 2035, at a compound annual growth rate (CAGR) of 19.1%. The CRISPR and Cas Genes Market is moderately consolidated, with leading biotechnology and life sciences companies focusing on expanding gene-editing platforms, therapeutic pipelines, and research tool portfolios. Market growth is driven by increasing adoption of CRISPR technologies in gene therapy, drug discovery, functional genomics, and agricultural biotechnology. Strategic collaborations, product innovations, licensing agreements, and rising investments in clinical research continue to strengthen the competitive landscape and accelerate commercialization of CRISPR-based solutions. For instance, in May 2025, CRISPR Therapeutics reported positive Phase 1 clinical data for CTX310, its in vivo CRISPR-based gene-editing therapy targeting cardiovascular disease, demonstrating a significant milestone in advancing lipid nanoparticle (LNP)-mediated gene editing for liver diseases.

Based on Technology, the CRISPR/Cas9 segment dominated the CRISPR and Cas Genes market in 2025 due to its established position as the most widely adopted gene-editing technology across research, drug discovery, and therapeutic development. Its high editing efficiency, ease of guide RNA design, cost-effectiveness, and extensive validation in academic and commercial laboratories have accelerated widespread adoption. CRISPR/Cas9 is extensively used in functional genomics, disease modeling, gene knockout studies, and preclinical gene therapy research. Strong availability of commercial kits, reagents, and standardized workflows, coupled with significant investments from biotechnology and pharmaceutical companies, continues to reinforce its leadership and broad application across life science research and clinical innovation.

Based on Application, the Gene Therapy segment is projected to register the fastest growth during the forecast period, driven by the rapid advancement of precision medicine and increasing clinical development of CRISPR-based therapeutics targeting inherited, rare, and oncology-related diseases. Growing regulatory support for gene-editing therapies, rising investments in biotechnology, and expanding numbers of clinical trials are accelerating market expansion. Continuous improvements in delivery technologies, enhanced editing accuracy, and reduced off-target effects are improving the safety and efficacy of CRISPR-enabled treatments. As more gene-editing therapies progress toward commercialization, demand for CRISPR technologies in therapeutic applications is expected to increase significantly throughout the forecast period.

Geographical Overview

North America dominated the CRISPR and Cas Genes market in 2025, supported by its well-established biotechnology ecosystem, strong presence of leading gene-editing companies, and substantial investments in genomic research and precision medicine. The region benefits from extensive funding from government agencies, academic institutions, and private investors, accelerating the development and commercialization of CRISPR-based therapeutics and research tools. The United States leads the regional market owing to its advanced healthcare infrastructure, large number of clinical trials, favorable research funding, and presence of major biotechnology and pharmaceutical companies. Canada further strengthens regional growth through government-backed genomics initiatives and increasing collaborations between research organizations and industry participants.

Asia-Pacific is projected to register the fastest growth during the forecast period, driven by expanding biotechnology research, increasing investments in gene-editing technologies, and growing government support for genomics and precision medicine. Countries such as China, Japan, South Korea, and India are rapidly strengthening their life sciences capabilities through increased R&D funding, establishment of advanced genomic research centers, and rising collaborations between academia and biotechnology companies. The region is also witnessing growing adoption of CRISPR technologies in agricultural biotechnology, drug discovery, and gene therapy research. Rising healthcare expenditure, expanding biopharmaceutical manufacturing, and supportive innovation policies are expected to further accelerate market growth across Asia-Pacific.

Key Trends and Drivers

Increasing Clinical Advancement of CRISPR-Based Gene Therapies:

The CRISPR and Cas Genes market is witnessing a strong trend toward the clinical advancement of gene-editing therapies as biotechnology companies expand trials targeting genetic, rare, and oncology-related diseases. Continuous improvements in CRISPR systems, including enhanced editing precision, novel Cas variants, and advanced delivery technologies, are improving therapeutic safety and efficacy. The growing number of clinical studies, regulatory designations, and commercialization efforts is accelerating the transition of CRISPR from research laboratories to clinical applications. This trend is further supported by increasing investments from pharmaceutical companies and strategic collaborations aimed at developing next-generation gene-editing treatments.

Rising Investments in Genomics Research and Precision Medicine:

Growing global investments in genomics research and precision medicine are a major driver of the CRISPR and Cas Genes market. Governments, biotechnology companies, pharmaceutical firms, and research institutions are significantly increasing funding to develop innovative gene-editing technologies for disease treatment, drug discovery, and functional genomics. The rising prevalence of genetic disorders and cancer, coupled with increasing demand for targeted therapies, is accelerating the adoption of CRISPR-based solutions. In addition, expanding research infrastructure, favorable funding programs, and technological advancements in genome editing are enabling broader commercialization and accelerating market growth across therapeutic, agricultural, and industrial biotechnology applications.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Component
• 2.8 Key Market Highlights by Process
• 2.9 Key Market Highlights by Functionality

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Genome Editing
  • 4.1.2 Genetic Engineering
  • 4.1.3 Gene Library
  • 4.1.4 CRISPR Plasmid
  • 4.1.5 CRISPR Enzyme
  • 4.1.6 CRISPR RNA
  • 4.1.7 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Kits and Reagents
  • 4.2.2 Cell Lines
  • 4.2.3 Plasmids
  • 4.2.4 Vectors
  • 4.2.5 Others
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 gRNA Design
  • 4.3.2 Cell Line Engineering
  • 4.3.3 Screening Services
  • 4.3.4 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 CRISPR/Cas9
  • 4.4.2 CRISPR/Cas12
  • 4.4.3 CRISPR/Cas13
  • 4.4.4 Others
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Biomedical Research
  • 4.5.2 Agricultural Biotechnology
  • 4.5.3 Industrial Biotechnology
  • 4.5.4 Drug Development
  • 4.5.5 Gene Therapy
  • 4.5.6 Diagnostics
  • 4.5.7 Others
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Pharmaceutical Companies
  • 4.6.2 Biotechnology Companies
  • 4.6.3 Academic and Research Institutes
  • 4.6.4 Contract Research Organizations
  • 4.6.5 Others
• 4.7 Market Size & Forecast by Component (2020-2035)
  • 4.7.1 Guide RNA
  • 4.7.2 Donor DNA Templates
  • 4.7.3 Cas Nucleases
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Process (2020-2035)
  • 4.8.1 Gene Knockout
  • 4.8.2 Gene Knock-In
  • 4.8.3 Gene Activation
  • 4.8.4 Gene Repression
  • 4.8.5 Others
• 4.9 Market Size & Forecast by Functionality (2020-2035)
  • 4.9.1 Targeted Genome Editing
  • 4.9.2 Functional Genomics
  • 4.9.3 Epigenome Editing
  • 4.9.4 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Component
    • 5.2.1.8 Process
    • 5.2.1.9 Functionality
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Component
    • 5.2.2.8 Process
    • 5.2.2.9 Functionality
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Component
    • 5.2.3.8 Process
    • 5.2.3.9 Functionality
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Component
    • 5.3.1.8 Process
    • 5.3.1.9 Functionality
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Component
    • 5.3.2.8 Process
    • 5.3.2.9 Functionality
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Component
    • 5.3.3.8 Process
    • 5.3.3.9 Functionality
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Component
    • 5.4.1.8 Process
    • 5.4.1.9 Functionality
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Component
    • 5.4.2.8 Process
    • 5.4.2.9 Functionality
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Component
    • 5.4.3.8 Process
    • 5.4.3.9 Functionality
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Component
    • 5.4.4.8 Process
    • 5.4.4.9 Functionality
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Component
    • 5.4.5.8 Process
    • 5.4.5.9 Functionality
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Component
    • 5.4.6.8 Process
    • 5.4.6.9 Functionality
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Component
    • 5.4.7.8 Process
    • 5.4.7.9 Functionality
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Component
    • 5.5.1.8 Process
    • 5.5.1.9 Functionality
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Component
    • 5.5.2.8 Process
    • 5.5.2.9 Functionality
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Component
    • 5.5.3.8 Process
    • 5.5.3.9 Functionality
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Component
    • 5.5.4.8 Process
    • 5.5.4.9 Functionality
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Component
    • 5.5.5.8 Process
    • 5.5.5.9 Functionality
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Component
    • 5.5.6.8 Process
    • 5.5.6.9 Functionality
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Component
    • 5.6.1.8 Process
    • 5.6.1.9 Functionality
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Component
    • 5.6.2.8 Process
    • 5.6.2.9 Functionality
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Component
    • 5.6.3.8 Process
    • 5.6.3.9 Functionality
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Component
    • 5.6.4.8 Process
    • 5.6.4.9 Functionality
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Component
    • 5.6.5.8 Process
    • 5.6.5.9 Functionality

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Editas Medicine
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 CRISPR Therapeutics
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Intellia Therapeutics
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Caribou Biosciences
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Beam Therapeutics
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Sangamo Therapeutics
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Cellectis
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Precision BioSciences
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Horizon Discovery
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Mammoth Biosciences
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Synthego
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Inscripta
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Pairwise Plants
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Locus Biosciences
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 eGenesis
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Arbor Biotechnologies
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Crispr Biotechnologies
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 GenEdit
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Graphite Bio
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Poseida Therapeutics
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us